Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF
requiring inotropic support is limited to case series.1 This study aimed to evaluate
ivabradine safety and tolerability in admitted cardiogenic shock patients who started on
dobutamine infusion for inotropic support.
Phase:
Phase 3
Details
Lead Sponsor:
The Young Investigator Group of Cardiovascular Research